Bradenton Research Center, Inc — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$15	1
2024	Research	$4,350	1
2023	Research	$97,126	17
2022	Research	$40,408	17
2021	Research	$39,130	108
2020	Research	$21,208	22
2019	Research	$65,437	7

Breakdown

Who paid Research payments · program years 2019–2025

Novo Nordisk AS $85,980 153 payments
Grifols Biologicals LLC $65,336 2 payments
Novartis Pharmaceuticals Corporation $44,308 5 payments
Ucb SA $41,267 4 payments
SK Life Science, Inc. $30,784 9 payments

Studies the money was for Research payments · program years 2019–2025

Ex9536-4388 $85,980 153 payments
A Multicenter, Randomized, Controlled Study To Evaluate The Efficacy and Safety of Short-Term Plasma Exchange Followed by Long-Term Plasmapheresis With Infusion of Human Albumin Combined With Intravenous Immunoglobulin In Patients With Mild-Moderate AD $65,336 2 payments
An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis $25,363 1 payment
A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ucb0599 in Study Participants With Early Parkinson's Disease $20,609 1 payment
A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ucb0599 in Study Participants With Early Parkinsons Disease $16,308 2 payments
A Pilot Open-Label, Randomized, Multi-Center, Parall El-Arm, of Acute VS Delay Ofatumumab Treatment D Uring An Acute Multiple Sclerosis Relapse $10,945 3 payments
1-Q3ras $10,391 3 payments
An Open-Label Multicenter Study to Assess Response to Covid-19 Vaccine in Participants With Multiple Sclerosis Treated With Ofatumumab 20 MG Subcutaneously $8,000 1 payment
Ykp3089c013 $5,871 1 payment
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects with Partial Onset Seizures, with Optional Open-Label Extension $5,306 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.